{"id":755672,"date":"2025-08-07T12:42:01","date_gmt":"2025-08-07T12:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=755672"},"modified":"2025-08-07T12:42:01","modified_gmt":"2025-08-07T12:42:01","slug":"moderate-to-severe-plaque-psoriasis-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-bristolmyers-squibb-akeso-biopharma-jiangsu-hengrui-medic","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/moderate-to-severe-plaque-psoriasis-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-bristolmyers-squibb-akeso-biopharma-jiangsu-hengrui-medic_755672.html","title":{"rendered":"Moderate to Severe Plaque Psoriasis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medic"},"content":{"rendered":"
\n
\"Moderate<\/a><\/div>\n
\n
Moderate to Severe Plaque Psoriasis Pipeline Analysis<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s, \u201cModerate To Severe Plaque Psoriasis – Pipeline Insight, 2025,\u201d report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Moderate To Severe Plaque Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n

DelveInsight’s analysis highlights that over 30 key companies are actively engaged in developing more than 30 treatment therapies for Moderate to Severe Plaque Psoriasis.<\/p>\n

Moderate to Severe Plaque Psoriasis Overview:<\/strong><\/p>\n

Moderate to severe plaque psoriasis is the most common type of psoriasis, accounting for 80–90% of cases. It is an autoimmune condition that speeds up skin cell turnover, resulting in thick, scaly plaques typically found on the elbows, knees, scalp, and back. It can also impact the nails, causing issues such as discoloration, pitting, or nail separation. Flare-ups may be triggered by infections, stress, or skin trauma, with symptoms often coming and going.<\/p>\n

The underlying cause of plaque psoriasis is not fully understood, but genetics are known to play a major role—about one-third of those affected have a family history. Specific gene mutations (PSORS1–PSORS9) have been associated with the condition, although environmental factors like infections or chemical exposure may also contribute. Diagnosis is usually clinical but may involve a skin biopsy to rule out other disorders.<\/p>\n

The condition can have a profound effect on emotional and physical well-being. While it is chronic and currently incurable, treatment focuses on symptom control and reducing flare-ups. Standard treatment options include topical corticosteroids, UV light therapy, vitamin D3 analogs, and retinoids. Recent advances in immunological research have significantly improved the effectiveness of available treatments, enhancing patients’ quality of life.<\/p>\n

Request for a detailed insights report on Moderate to Severe Plaque Psoriasis pipeline insights<\/a><\/strong><\/p>\n

“Moderate to Severe Plaque Psoriasis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Moderate to Severe Plaque Psoriasis Therapeutics Market.<\/p>\n

Key Takeaways from the Moderate to Severe Plaque Psoriasis Pipeline Report<\/strong><\/p>\n